Myelofibrosis

In this video, Aaron T. Gerds, MD, MS, discussed the TRANSFORM-1 and MANIFEST-2 trials into combination therapies in myelofibrosis, both of which were presented at the ASH Annual Meeting and Exposition.

In this video, Aaron T. Gerds, MD, MS, discussed the TRANSFORM-1 and MANIFEST-2 trials into combination therapies in myelofibrosis, both of which were presented at the ASH Annual Meeting and Exposition.

SAN DIEGO — Treatment with a selective PIM1 kinase inhibitor showed positive clinical reactions in a sample of 23 patients with relapsed/refractory myelofibrosis, according to preliminary data presented at ASH Annual Meeting.

SAN DIEGO — Treatment with fedratinib led to “superior” spleen volume reduction and symptom response rates in patients with myelofibrosis previously treated with ruxolitinib, according to data presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Pacritinib may provide a “unique survival advantage” for patients with myelofibrosis also exhibiting moderate or severe thrombocythemia, according to data from the PERSIST-2 study, presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Navitoclax added to ruxolitinib led to a significant improvement in spleen volume reduction compared with placebo among patients with untreated myelofibrosis, study results presented at ASH Annual Meeting and Exposition showed.

The combination of pelabresib plus ruxolitinib significantly increased the proportion of patients with myelofibrosis who achieved a clinically meaningful reduction in spleen volume, according to the agent’s manufacturer.

An analysis of online conversations among health care professionals on social media during September revealed mixed reactions toward newly updated messenger RNA COVID-19 vaccines.

The FDA approved momelotinib for treatment of patients with myelofibrosis and anemia regardless of prior myelofibrosis therapy.